作为HIV感染中缺陷性T淋巴细胞的替代标志物，CD4:CD8比值近年来再次引起了广泛关注 ... 参考类别为 CD4:CD8 比率滞后 12 m ≥1.0，CD4 滞后 12 m ≥50 cells/μL，HI 病毒引线滞后 12 m ≤200 ...

Researchers from the Josep Carreras Leukaemia Research Institute have found that the efficacy of varni-cel, a CAR-T infusion ...

The development of CAR-T technology in recent years has been a major milestone in the fight against cancer. These sort of ...

“Most notably, we will be showcasing what we believe to be the first iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells. The engineerability of ...

The development of CAR-T cell therapy marks a major breakthrough in cancer treatment. These “living drugs” are T-cells genetically engineered to spread through the body, identify, and destroy cancer ...

In a recent study published at *Cell Reports Medicine*the team identified three key success markers: the CD4:CD8 ratio, exhaustion signals and the expansion of gamma-delta cytotoxic T-cells. Taken ...

In a recent study published at Cell Reports Medicine the team identified three key success markers: the CD4:CD8 ratio, exhaustion signals and the expansion of gamma-delta cytotoxic T-cells.